Traders assign an 87% probability against a new COVID variant of concern emerging before 2027 primarily because current SARS-CoV-2 evolution remains confined to Omicron-descendant lineages under close surveillance, with no recent escalation to official VOC status. As of October 2026, variants under monitoring such as XFG and BA.3.2 show immune escape traits and seasonal circulation but lack evidence of heightened severity, transmissibility, or immune evasion sufficient to trigger a major public health shift. Widespread population immunity from prior infections and updated vaccines continues to limit severe outcomes, while genomic data indicate these strains cocirculate without displacing predecessors rapidly. Reduced global sequencing volumes introduce some uncertainty, yet the pattern of gradual subvariant drift rather than abrupt leaps supports the market's assessment of low near-term risk for a new designation.